Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.76 |
| ▸ | PKM | P14618 | 1/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.73 |
| ▸ | CTSS | P25774 | 3/20 | 0.72 |
| ▸ | LMNA | P02545 | 2/20 | 0.72 |
| ▸ | THRB | P10828 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13405879 | 0.93 | TP53 (0.86) | TP53HSD17B10PKMSMN1; SMN2CTSS | |
| SCHEMBL13406007 | 0.89 | TP53 (0.81) | TP53HSD17B10PKMSMN1; SMN2CTSS | |
| SCHEMBL13405921 | 0.88 | TP53 (0.79) | TP53HSD17B10PKMSMN1; SMN2CTSS | |
| SCHEMBL13406216 | 0.86 | HSD17B10 (0.77) | TP53HSD17B10PKMSMN1; SMN2CTSS | |
| SCHEMBL13405922 | 0.86 | TP53 (0.76) | TP53HSD17B10PKMSMN1; SMN2CTSS | |
| SCHEMBL13405877 | 0.86 | HSD17B10 (1.00) | TP53HSD17B10PKMSMN1; SMN2CTSS | |
| SCHEMBL13406063 | 0.85 | HSD17B10 (0.78) | TP53HSD17B10PKMSMN1; SMN2CTSS | |
| SCHEMBL13406034 | 0.85 | CTSS (0.75) | TP53HSD17B10PKMSMN1; SMN2CTSS | |
| SCHEMBL13406282 | 0.85 | PKM (0.82) | TP53HSD17B10PKMSMN1; SMN2CTSS | |
| SCHEMBL13406056 | 0.84 | PKM (0.85) | TP53HSD17B10PKMSMN1; SMN2CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7705031-B2 | Benzimidazoles useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-27 | — | — | US | disclosed |
| US-7705031-B2 | Benzimidazoles useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-27 | — | — | US | disclosed |
| US-20080306129-A1 | BENZIMIDAZOLES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2008-12-11 | — | — | US | disclosed |
| US-20080306129-A1 | BENZIMIDAZOLES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2008-12-11 | — | — | US | disclosed |
| US-7309716-B2 | Benzimidazoles useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-12-18 | — | — | US | disclosed |
| US-7309716-B2 | Benzimidazoles useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306129-A1 | BENZIMIDAZOLES USEFUL AS MODULATORS OF ION CHANNELS | KCNJ11, KCNJ1, KCNJ2 | TP53 4215/4885HSD17B10 3940/4885PKM 1128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.